News

Patients testing positive for SARS-CoV-2 after recovery and negative tests are re-examined to determine if they are reinfected and/or infectious.

Gilead has announced that its investigational long-acting HIV-1 capsid inhibitor, lenacapavir, has achieved its primary endpoint in a phase 2/3 CAPELLA trial.

Phase 2 results include a large cohort of seniors in the study.

For the first time, prescribed users at suspected risk of COVID-19 can receive rapid results from home.

The US Food and Drug Administration has granted breakthrough therapy designation for an investigational drug, a long-acting, injectable cabotegravir for HIV pre-exposure-prophylaxis (PrEP).

The investigational vaccine is being reported as 95% effective.

SARS-CoV-2 outbreaks on 16 different mink farms in the Netherlands have been identified showing transmission between humans and minks.

The data comes from a phase 1/2 trial with the CoronaVac vaccine.

More than 13 million children did not receive their first DTP vaccine dose in 2019—and investigators anticipate the 2020 rate will be worse.

A survey of clinicians found that despite planning for resource limitations during the coronavirus 2019 (COVID-19) pandemic, clinicians still faced difficult decisions at bedside.

New study finds casual links between obese people and the potential for a higher risk of COVID-19 infection

Non-pharmaceutical interventions (NPIs) are not only effective against COVID-19, but also respiratory infections.

Phase 2 data hints the immune response-modulating therapy could play a role in burdened hospital settings.

Further evidence demonstrating the lack of efficacy of hydroxychloroquine as a treatment for coronavirus disease 2019 (COVID-19) was detailed in a new randomized, multicenter, blinded, placebo-controlled study published in JAMA.

Data show none of the treated volunteers to develop COVID-19 experienced a severe form of the disease, versus 11 given placebo.

The Vanderbilt Professor of Preventive Medicine shares thoughts on the first potential COVID-19 vaccine, at a time of record new daily cases.

The biotechnology has reached it COVID-19 case accrual mark, and announced plans to submit data to an independent review board.